Mucopolysaccharidosis IVIIB therapeutic - Dorphan

Drug Profile

Mucopolysaccharidosis IVIIB therapeutic - Dorphan

Latest Information Update: 15 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator DORPHAN S.A.
  • Class Imino sugars; Pharmacological chaperones
  • Mechanism of Action Glycoside hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Mucopolysaccharidosis IV

Most Recent Events

  • 15 Jul 2016 Mucopolysaccharidosis IVIIB therapeutic - Dorphan is available for licensing as of 15 Jul 2016.
  • 15 Jul 2016 Preclinical trials in Mucopolysaccharidosis IV in Switzerland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top